-
2022-06-17
Strategic Cooperation Agreement with SHAPHAR
June 16th, 2022, Nuance Pharma signed Strategic Cooperation Agreement with Shanghai Pharmaceutical Co., Ltd. (Shanghai Pharma).
-
2022-06-09
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).
-
2022-03-04
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio™, its nasal spray for protection against airborne viruses and allergens, with Nuance Phar
-
2022-01-06
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.
-
2021-12-23
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Aerogen Pharma announces an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
-
2021-06-10
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
Verona Pharma plc (Nasdaq: VRNA) and Nuance Pharma Limited today announce that the companies have entered into an agreement granting Nuance Pharma, a Shanghai
-
2020-12-08
Nuance Pharma Closes Series D Financing
Nuance Pharma announced that it has successfully closed its Series D financing which amounted to US$181 million of funding.
-
2020-10-21
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties
Contact PR
